$684.29 Mn EConsent In Healthcare Market Trends and Forecasts, 2020-2024 & 2025-2030: Enhanced Patient Engagement Driving Growth, Technological Advancements Gaining Traction
The increasing integration of eConsent with telemedicine and electronic health records (EHRs) is accelerating adoption across healthcare settings. Acknowledging this shift, global institutions such as the World Health Organization (WHO) have highlighted the ethical and legal dimensions of eConsent implementation, reinforcing its growing importance in modern healthcare systems.
EConsent In Healthcare Market
Dublin, June 05, 2025 (GLOBE NEWSWIRE) -- The "EConsent In Healthcare Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F" report has been added to ResearchAndMarkets.com's offering.The EConsent In Healthcare Market was valued at USD 351.26 Million in 2024, and is expected to reach USD 684.29 Million by 2030, rising at a CAGR of 11.76%
The healthcare sector is undergoing a transformative shift, with electronic informed consent (eConsent) emerging as a vital innovation. This digital solution enhances patient-provider communication while streamlining documentation and administrative workflows. eConsent empowers patients to participate more actively in their care decisions by improving accessibility and comprehension through multimedia tools and digital platforms.
Key Market Drivers
Enhanced Patient Engagement is Driving the Global EConsent In Healthcare MarketThe growing shift toward digital healthcare delivery is fundamentally reshaping how patients interact with medical providers, and enhanced patient engagement is a primary force behind the expansion of the eConsent market. By incorporating user-friendly multimedia content - such as animations, simplified text, and videos - eConsent platforms help patients better understand procedures, risks, and benefits.This accessibility improves patient comprehension and supports informed decision-making. These platforms also allow two-way communication, enabling patients to ask questions and clarify concerns at their own convenience, which enhances trust and reduces uncertainty. Integration with electronic health records (EHRs) gives patients greater visibility into their medical history and treatment options. Additionally, the ability to provide consent remotely ensures inclusive access to care, especially for those relying on telemedicine, reinforcing the role of eConsent in supporting modern, patient-centric healthcare.Key Market Challenges
Regulatory ChallengesNavigating regulatory compliance is one of the most significant hurdles in the global eConsent in healthcare market. Due to healthcare's complex regulatory environment, eConsent platforms must meet diverse standards regarding patient data privacy, security, and documentation across different countries and jurisdictions.
Adherence to frameworks such as the General Data Protection Regulation (GDPR) in Europe and the Health Insurance Portability and Accountability Act (HIPAA) in the United States presents both technical and financial challenges. These evolving regulations require eConsent providers to consistently update their systems, which can be both resource-intensive and time-consuming. Ensuring compliance while maintaining functionality and usability across various healthcare systems adds an additional layer of complexity to solution deployment.Key Market Trends
Technological AdvancementsAdvancements in technology are significantly reshaping the eConsent landscape. The adoption of electronic signature capabilities has enabled the complete digitalization of consent processes, eliminating paper-based workflows and improving document management. The widespread use of smartphones and mobile applications has further increased the reach of eConsent, allowing patients to review, interact with, and sign forms on-the-go.
These platforms can embed interactive tools and multimedia content to enhance patient understanding. In addition, blockchain technology is gaining traction as a solution for securing consent data, offering a transparent and tamper-resistant method of storing sensitive information. These innovations collectively contribute to higher patient confidence, operational efficiency, and regulatory compliance in healthcare settings.
Key Attributes:
Report Attribute
Details
No. of Pages
182
Forecast Period
2024 - 2030
Estimated Market Value (USD) in 2024
$351.26 Million
Forecasted Market Value (USD) by 2030
$684.29 Million
Compound Annual Growth Rate
11.7%
Regions Covered
Global
Report Scope:
Competitive LandscapeCompany Profiles: Detailed analysis of the major companies present in the Global EConsent In Healthcare Market.
Veeva Systems Inc.
Wellbeing Software, a Citadel Group
Florence Healthcare Inc.
Concentric Health Ltd
5thPort, LLC
Cloudbyz Inc.
Calysta EMR
Interlace Health, LLC
Thieme Compliance GmbH
OpenClinica, LLC
eConsent In Healthcare Market, By Platform:
Cloud-based
Web-based
eConsent In Healthcare Market, By Enrollment Type:
On-site
Remote
eConsent In Healthcare Market, By Form Type:
General Consent
General Consent with Specific Denial(s)
General Denial with Specific Consent(s)
General Denial
eConsent In Healthcare Market, By Region:
North America
United States
Canada
Mexico
Europe
France
United Kingdom
Italy
Germany
Spain
Asia-Pacific
China
India
Japan
Australia
South Korea
South America
Brazil
Argentina
Colombia
Middle East & Africa
South Africa
Saudi Arabia
UAE
For more information about this report visit https://www.researchandmarkets.com/r/mulvc1
About ResearchAndMarkets.comResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Attachment
EConsent In Healthcare Market
CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood,Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
BrainDefender Research Announces Launch of New Cognitive Support Formula for Adults
Plant-Based Supplement Includes Five Individual Ingredients Studied for Their Role in Supporting Memory and Focus Denver, June 06, 2025 (GLOBE NEWSWIRE) -- BrainDefender Research today announced the launch of , a new cognitive wellness formula developed to support focus, mental clarity, and memory in adults. Manufactured in a GMP-certified facility in the United States, the product is designed for individuals seeking to maintain healthy cognitive function through natural, plant-based supplementation. The new formula features a combination of Ginkgo Biloba, Bacopa Monnieri, Huperzine-A, Phosphatidylserine, and N-Acetyl-L-Carnitine—ingredients that have each been individually studied for their potential roles in brain function. BrainDefender Research emphasizes that the supplement is intended for use as part of a wellness routine to support cognitive performance and healthy aging. 'Consumer interest in natural brain support has grown significantly in recent years,' said a spokesperson for BrainDefender Research. 'We developed this product to offer adults a well-rounded option for supporting mental clarity, focus, and memory performance using recognizable, research-supported ingredients.' The company recommends consistent daily use over a 90-day period for best results and offers a 60-day refund policy for customer satisfaction. The product is available for purchase in 30-day, 90-day, and 180-day supply options to accommodate individual wellness goals. AvailabilityBrainDefender Memory Support Supplement can be ordered directly through the company's official website and is also offered via the ClickBank platform. Domestic orders are typically delivered within 5–7 business days, while international shipping may take 10–12 business days. About BrainDefender ResearchBrainDefender Research is a U.S.-based wellness company focused on the development of cognitive support supplements using plant-based ingredients. All products are manufactured in GMP-certified facilities to ensure quality and safety in every batch. DisclaimerThese statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. Individuals should consult a licensed healthcare provider before beginning any new supplement routine, especially if taking medications or managing a medical condition. Media Contact Email: support@ Phone: (855) 473-4405 CONTACT: Email: support@ Phone: (855) 473-4405Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
CNN
an hour ago
- CNN
As measles spreads across the Americas, outbreaks in Mexico and Canada have also turned deadly
As measles cases in the United States continue to mount, neighboring countries Canada and Mexico are also experiencing significant outbreaks – all of which have been linked to at least one death. On Thursday, the chief medical officer of health of the Canadian province Ontario announced that an infant who was born prematurely with a measles infection had died. 'The infant contracted the virus before birth from their mother, who had not received the measles, mumps and rubella (MMR) vaccine,' Dr. Kieran Moore said in a statement. 'While measles may have been a contributing factor in both the premature birth and death, the infant also faced other serious medical complications unrelated to the virus.' At least four people have died from measles in Mexico in 2025, and three people have died in the US: two children in Texas and one adult in New Mexico, all of whom were unvaccinated. This years' measles outbreaks are the biggest that Canada and Mexico have seen in decades, and the World Health Organization has warned that the 'overall risk of measles in the Americas Region is considered high.' Low vaccination rates are a key driver of this elevated risk assessment, the agency said. Mexico has reported at least 1,520 measles cases as of late May, according to data from the Pan American Health Organization. Canada reached measles elimination status in 1998, meaning that there has not been continuous spread of the virus for more than a year. But there have already been more cases reported so far this year than there were in the previous 27 years combined. At least 2,755 measles cases have been reported in Canada so far this year, according to federal data that was last updated on Monday, the vast majority of those which have been in Ontario residents. And the US has reported at least 1,168 measles cases so far this year, according to federal data published Friday – nearly 80% of which are associated with an outbreak centered in West Texas that has spread to New Mexico, Oklahoma and possibly Canada. It's the second highest number of cases that the US has reported since achieving measles elimination status in 2000. Significant shares of the measles outbreaks in the US, Canada and Mexico have been concentrated in Mennonite communities that are closely connected to each other – and that have historically had low vaccination rates due largely to minimal interactions with formal health care systems. However, in a recent webinar, experts from the Pan American Health Organization did not formally link outbreaks in the three countries to each other. 'The outbreak [in Mexico] started in Chihuahua, at the heart of Mennonite communities, who were very close to Texas through the border, but they're also close to other Mennonite communities in Canada,' Dr. Alvaro Whittembury, regional adviser for the Comprehensive Immunization Special Program, said in a presentation on Wednesday. 'It's important to show that although at first the outbreak starts in Mennonite communities … the vast majority of cases are outside of these communities, and they are sustained in the general population.' Only a small share of confirmed cases in the Americas have identified genetic sequences, experts from the Pan American Health Organization said, and there haven't been enough identical sequences to explicitly link cases across countries. In April, Mexico issued a warning for people traveling to the US and Canada due to high measles case rates. The US Centers for Disease Control and Prevention has also stepped up its guidance for travelers, advising that anyone traveling internationally should be vaccinated with two doses of the MMR vaccine. 'Anyone who is unvaccinated is at risk and I urge everyone, but especially those who may become pregnant, to ensure they have received two doses of the MMR vaccine, which will protect both a parent and baby,' Moore said in his statement Thursday. 'This vaccine has been safely used for over 50 years and is highly effective. Two doses provide nearly 100 per cent protection.'
Yahoo
2 hours ago
- Yahoo
PolyPid to Host Conference Call and Webcast to Discuss D-PLEX₁₀₀ SHIELD II Phase 3 Trial Topline Results on Monday, June 9, 2025
PETACH TIKVA, Israel, June 06, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD), ('PolyPid' or the 'Company'), a late-stage biopharma company aiming to improve surgical outcomes, today announced that it will host a conference call and webcast to report topline data for the SHIELD II Phase 3 trial, evaluating D-PLEX100 for the prevention of surgical site infections in patients undergoing abdominal colorectal surgery, on Monday, June 9, at 8:30 a.m. ET. To ensure you are connected prior to the beginning of the call, PolyPid suggests registering a minimum of 5 minutes before the start of the call. Conference Call Dial-In & Webcast Information: Date: Monday, June 9, 2025 Time: 8:30 AM Eastern Time Conference Call: Webcast: About PolyPid PolyPid Ltd. (Nasdaq: PYPD) is a late-stage biopharma company aiming to improve surgical outcomes. Through locally administered, controlled, prolonged-release therapeutics, PolyPid's proprietary PLEX (Polymer-Lipid Encapsulation matriX) technology pairs with Active Pharmaceutical Ingredients (APIs), enabling precise delivery of drugs at optimal release rates over durations ranging from several days to months. PolyPid's lead product candidate D-PLEX100 is in Phase 3 clinical trial for the prevention of abdominal colorectal surgical site infections. In addition, the Company is currently in preclinical stages to test the efficacy of OncoPLEX for the treatment of solid tumors, beginning with glioblastoma. For additional Company information, please visit and follow us on Twitter and LinkedIn. Contacts:PolyPid Ltd. Ori WarshavskyCOO – US908-858-5995IR@ Investors:Brian RitchieLifeSci Advisors212-915-2578britchie@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
